IDEAS home Printed from https://ideas.repec.org/a/cup/hecopl/v19y2024i2p216-233_5.html
   My bibliography  Save this article

Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit

Author

Listed:
  • Kleining, Katrin
  • Laufenberg, Jan
  • Thrun, Philip
  • Ehlert, Dorothee
  • Wasem, Jürgen
  • Bartol, Arne

Abstract

Introduction Since 2011, the prices for all new drugs in Germany are negotiated based on a benefit assessment. The purpose of this study was to analyze the price regulation of drugs with unproven additional benefit. Methods Benefit assessment procedures from 2011 to 2020 were reviewed and selected through AMNOG Monitor and Lauer Taxe. Negotiated annual therapy costs, the annual costs of the most cost-efficient appropriate comparative therapy (ACT) and the potential budget impact for 33 included procedures were calculated. Results 55% of the included drugs achieved a negotiated price higher than the most cost-efficient ACT, 3% were identified as equal and 42% showed lower negotiated prices. The potential savings exceeded expenditures by around EUR 523.5 m. After price flexibility was adopted by the legislator in 2017, the overall potential savings still outweighed the expenditures by around EUR 62 m. Conclusions Our analysis shows that making price negotiations more flexible by law does not undermine the fundamental aim of the AMNOG, which is to avoid additional expenditure without increased patient benefit. The regulation can thus fulfill the objective provided by the legislature of keeping drugs without proven additional benefits in the German healthcare system.

Suggested Citation

  • Kleining, Katrin & Laufenberg, Jan & Thrun, Philip & Ehlert, Dorothee & Wasem, Jürgen & Bartol, Arne, 2024. "Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit," Health Economics, Policy and Law, Cambridge University Press, vol. 19(2), pages 216-233, April.
  • Handle: RePEc:cup:hecopl:v:19:y:2024:i:2:p:216-233_5
    as

    Download full text from publisher

    File URL: https://www.cambridge.org/core/product/identifier/S1744133123000117/type/journal_article
    File Function: link to article abstract page
    Download Restriction: no
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:cup:hecopl:v:19:y:2024:i:2:p:216-233_5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Kirk Stebbing (email available below). General contact details of provider: https://www.cambridge.org/hep .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.